Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients

Status unconfirmed

Conditions studied: Colon Cancer

In brief

The goal of this research study is to identify biologic and lifestyle factors that may increase a person's risk of developing a recurrence (return) of colon cancer.

Key facts

Study ID

NCT00354705

Run by

M.D. Anderson Cancer Center

People needed

200

Starts

2006-01-01

Expected to finish

2020-01-01

Last updated by the study team

2019-05-10

Who can join

Age: 14 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically proven adenocarcinoma of the colon. Those patients that do not have tissue available at MDACC for analysis will be eligible to participate in the blood, questionnaire and data portion of the study. They will not participate in the tissue portion of this study.
• AJCC stage II [T3-4(subscript)N0(subscript)M0(subscript)]or stage III [TX(subscript)N1-3(subscript)M0(subscript)].
• Age >= 14 yrs old.
• If the patient elects to receive chemotherapy and it is to be administered outside of M. D. Anderson Cancer Center (MDACC), the patient must agree to complete all subsequent surveillance at M.D. Anderson Cancer Center if participating in this clinical trial.
• Ability to understand and the willingness to sign the written informed consent/authorization document.

You may not qualify if…

• Patients who have initiated adjuvant chemotherapy prior to participating in this study will not be included.
• Patients with known history of familial adenomatous polyposis (FAP), hereditary nonpolyposis colorectal cancer (HNPCC), and any other hereditary polyposis syndrome (Muir Torre, Gardner's Syndrome, etc) will be excluded since these patients are at increased risk for second primary malignancies and are at higher risk of recurrent disease.
• No prior malignancies (excluding non-melanomatous skin neoplasms) over the past 5 years.
• Patients with a known diagnosis of HIV/AIDS or Hepatitis C will be excluded from this study due to their increased risk of second primary malignancies that may complicate appropriate analysis of DFS.
• Patients who are unable to self-administer the protocol questionnaire will be excluded from this study.

Where it is running

• University of Texas MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.